Synergistic role of simultaneous PET/MRI-MRS in soft tissue sarcoma metabolism imaging

详细信息    查看全文

• 作者：Xiaomeng Zhang^a ; ¹ ; ^{zhang@pet.mgh.harvard.edu" class="auth_mail" title="E-mail the corresponding author} ; Yen-Lin E. Chen^a ; ^b ; ¹ ; Ruth Lim^a ; Chuan Huang^a ; ^c ; Ivan A. Chebib^d ; Georges El Fakhri^a ; ^{elfakhri@pet.mgh.harvard.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Simultaneous PET/MR ; PET guided MR spectroscopy ; Soft tissue sarcoma
• 刊名：Magnetic Resonance Imaging
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：34
• 期：3
• 页码：276-279
• 全文大小：732 K

文摘

The primary objective of this study was to develop and validate simultaneous PET/MRI-MRS as a novel biological image-guided approach to neoadjuvant radiotherapy (RT) and/or chemoradiation (chemoRT) in soft tissue sarcomas (STS). A patient with sarcoma of the right thigh underwent PET/MRI scan before and after neoadjuvant (preoperative) radiotherapy. The magnetic resonance imaging (MRI) and 2-deoxy-2-[fluorine-18]-fluoro-D-glucose-Positron Emission Tomography (¹⁸F-FDG-PET) scans were performed simultaneously. In the post-radiation scan, magnetic resonance spectroscopy (MRS) was subsequently acquired with volume of interest positioned in a residual hyper-metabolic region detected by PET. Post-radiation PET/MRI showed a residual T2-hyperintense mass with significantly reduced ¹⁸F-FDG-uptake, compatible with near complete response to radiotherapy. However, a small region of residual high ¹⁸F-FDG uptake was detected at the tumor margin. MRS of this region had similar metabolite profile as normal tissue, and was thus considered false positive on PET scan. Pathology results were obtained after surgery for confirmation of imaging findings.